BioSight is a private, clinical-stage biotechnology company focused on developing innovative therapeutics for hematological malignancies and disorders. Their lead product, BST-236 (aspacytarabine), is a proprietary anti-metabolite designed to address unmet medical needs by enabling high-dose chemotherapy.